AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Launchavutometinib potassium and defactinib hydrochloride
NDAORALCAPSULE, TABLETPriority Review
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (avutometinib potassium and defactinib hydrochloride) by Verastem Oncology is mek1 inhibitor. Approved for ovarian cancer. First approved in 2025.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVMAPKI FAKZYNJA CO-PACK is a copackaged oral combination of avutometinib potassium (MEK1 inhibitor) and defactinib hydrochloride (FAK/Pyk2 inhibitor) approved for ovarian cancer. The dual mechanism targets the RAS/MAPK pathway via MEK inhibition while simultaneously blocking FAK-mediated signaling, with synergistic anti-tumor effects demonstrated in KRAS-mutant and low-grade serous ovarian cancer models.
Growth16.7 years to LOE
Early-stage launch product with 18 linked roles indicates rapid field team expansion and growing commercial infrastructure investment by Verastem Oncology.
Mechanism of Action
MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines…
Indications (1)
Worked on AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) at Verastem Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.